Has Monica Grafals, MD received payments from drug or device companies?

Yes. Drug and device makers reported $400,510 in general payments to Monica Grafals, MD across 392 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Monica Grafals, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Monica Grafals, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Monica Grafals, MD

Internal Medicine · Avon, CONPI 1578622320

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $294,470 of the $400,510 with a category attached, or 73.5%. Mallinckrodt Hospital Products Inc. accounts for 62.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $145,579 and has fallen 76.3% since, to $34,519 in 2025. Among internal medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$400,510in general payments, 2019–2025

Across 392 payments — averaging $1021.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Mallinckrodt Hospital Products Inc.$249K
Mallinckrodt Enterprises LLC$146K
Veloxis Pharmaceuticals, Inc.$4K
Kaneka Medical America LLC$2K
Amgen$484
ANI Pharmaceuticals, Inc.$125
plus $58 from 3 others

$272,500in research payments, 2019–2025

Across 3 payments — averaging $90,833 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Mallinckrodt Hospital Products Inc.$250K
Mallinckrodt Enterprises LLC$23K

What the payments were for

Consulting fees$13,8483%
Speaking & faculty fees$294,47074%
Travel & lodging$84,18221%
Food & beverage$7,9162%
Education$940%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Mallinckrodt Hospital Products Inc.	225	$248,537
Mallinckrodt Enterprises LLC	146	$145,567
Veloxis Pharmaceuticals, Inc.	4	$3,874
Kaneka Medical America LLC	2	$1,865
Amgen(2 entities)	7	$484
ANI Pharmaceuticals, Inc.	5	$125
Calliditas Therapeutics US Inc.	1	$27
Bayer	1	$20
Vifor Pharma, Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ACTHAR$389,825
Envarsus$3,874
Liposober$1,000
LIPOSORBER$865
KRYSTEXXA$222

How this compares

$400,510 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado →

Medicare billing

Part B allowed, 2024

$86,617

Medicare patients

321

Services billed

1,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	95	$59,985
OzempicSemaglutide	22	$29,033
XareltoRivaroxaban	42	$25,563
TrulicityDulaglutide	17	$16,243
MyrbetriqMirabegron	20	$15,970
Tresiba Flextouch U-100Insulin Degludec	19	$6,545
ArexvyRsvpref3 Antigen/As01e/Pf	13	$3,912
PremarinEstrogens, Conjugated	22	$2,516
SynthroidLevothyroxine Sodium	26	$2,393
Brimonidine Tartrate	13	$2,337
Atorvastatin Calcium	209	$2,213
Levothyroxine Sodium	252	$2,211
Rosuvastatin Calcium	134	$1,697
Gabapentin	110	$1,448
Metoprolol Succinate	102	$1,441

Paid to pharmacies, not to this prescriber.

Other internal medicine in Avon

Gilad GordonBoulder$476K
Kathryn PolovitzParker$403K
Luke WebbColorado Springs$287K
Samuel PiedadColorado Springs$154K
Sophia AmbrusoLittleton$62K
Kristine KuhnAurora$61K
Kenneth OleszekDenver$60K
Munni SelagamsettyColorado Springs$55K
Robert KeithDenver$49K
Elena AnisimovaDenver$36K

See the full list for Colorado →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →